搜尋
Alnylam Pharmaceuticals Inc
ALNY318.850USD
-9.880-3.01%
收盤 04/02, 16:00（美東）報價延遲15分鐘
16.55B總市值
133.13本益比TTM
關於 Alnylam Pharmaceuticals Inc 公司
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.
Alnylam Pharmaceuticals Inc簡介
公司代碼ALNY
公司名稱Alnylam Pharmaceuticals Inc
上市日期May 28, 2004
CEOGreenstreet (Yvonne L)
員工數量2230
證券類型Ordinary Share
年結日May 28
公司地址675 W Kendall St
城市CAMBRIDGE
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編02142-1168
電話16175518200
網址https://www.alnylam.com/
公司代碼ALNY
上市日期May 28, 2004
CEOGreenstreet (Yvonne L)
Alnylam Pharmaceuticals Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Yvonne L. Greenstreet, M.D.
Dr. Yvonne L. Greenstreet, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
96.10K
+4.28%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
61.86K
+0.15%
Mr. Tolga Tanguler
Mr. Tolga Tanguler
Chief Commercial Officer
Chief Commercial Officer
34.30K
+2.51%
Dr. Dennis A. Ausiello, M.D.
Dr. Dennis A. Ausiello, M.D.
Independent Director
Independent Director
4.41K
--
Dr. Margaret A. Hamburg, M.D.
Dr. Margaret A. Hamburg, M.D.
Independent Director
Independent Director
911.00
+85.07%
Dr. Olivier Brandicourt, M.D.
Dr. Olivier Brandicourt, M.D.
Independent Director
Independent Director
775.00
--
Mr. Peter N. Kellogg
Mr. Peter N. Kellogg
Independent Director
Independent Director
775.00
--
Mr. David E. I. Pyott, CBE
Mr. David E. I. Pyott, CBE
Independent Director
Independent Director
--
--
Ms. Amy W. Schulman, J.D.
Ms. Amy W. Schulman, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Pushkal P. Garg, M.D.
Dr. Pushkal P. Garg, M.D.
Executive Vice President, Chief Research and Development Officer
Executive Vice President, Chief Research and Development Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Yvonne L. Greenstreet, M.D.
Dr. Yvonne L. Greenstreet, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
96.10K
+4.28%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
61.86K
+0.15%
Mr. Tolga Tanguler
Mr. Tolga Tanguler
Chief Commercial Officer
Chief Commercial Officer
34.30K
+2.51%
Dr. Dennis A. Ausiello, M.D.
Dr. Dennis A. Ausiello, M.D.
Independent Director
Independent Director
4.41K
--
Dr. Margaret A. Hamburg, M.D.
Dr. Margaret A. Hamburg, M.D.
Independent Director
Independent Director
911.00
+85.07%
Dr. Olivier Brandicourt, M.D.
Dr. Olivier Brandicourt, M.D.
Independent Director
Independent Director
775.00
--
收入明細
單位: USD更新時間: 4月2日 週四
單位: USD更新時間: 4月2日 週四
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
業務USD
名稱
營收
佔比
AMVUTTRA
2.31B
62.30%
Roche
394.88M
10.63%
GIVLAARI
308.49M
8.31%
Other
218.55M
5.88%
OXLUMO
191.44M
5.15%
其他
286.75M
7.72%
地區USD
名稱
營收
佔比
United States
2.07B
55.67%
Europe
651.09M
17.53%
Net revenues from collaborations
553.37M
14.90%
Rest of World
267.93M
7.21%
Royalty revenue
174.02M
4.69%
業務
地區
業務USD
名稱
營收
佔比
AMVUTTRA
2.31B
62.30%
Roche
394.88M
10.63%
GIVLAARI
308.49M
8.31%
Other
218.55M
5.88%
OXLUMO
191.44M
5.15%
其他
286.75M
7.72%
股東統計
更新時間: 2月19日 週四
更新時間: 2月19日 週四
持股股東
股東類型
持股股東
持股股東
佔比
Capital World Investors
12.29%
Fidelity Management & Research Company LLC
11.37%
The Vanguard Group, Inc.
10.17%
BlackRock Institutional Trust Company, N.A.
5.31%
Capital Research Global Investors
5.11%
其他
55.74%
持股股東
持股股東
佔比
Capital World Investors
12.29%
Fidelity Management & Research Company LLC
11.37%
The Vanguard Group, Inc.
10.17%
BlackRock Institutional Trust Company, N.A.
5.31%
Capital Research Global Investors
5.11%
其他
55.74%
股東類型
持股股東
佔比
Investment Advisor
67.86%
Investment Advisor/Hedge Fund
23.38%
Hedge Fund
3.66%
Sovereign Wealth Fund
1.85%
Research Firm
1.78%
Bank and Trust
1.46%
Pension Fund
1.46%
Individual Investor
0.45%
Private Equity
0.22%
機構持股
更新時間: 10 小時前
更新時間: 10 小時前
報告期間
機構數
持股數
持股佔比
持股變動
2026Q1
1578
134.92M
101.73%
-3.85M
2025Q4
1441
132.38M
102.07%
-8.88K
2025Q3
1468
132.43M
102.39%
+2.53M
2025Q2
1335
129.81M
101.55%
+2.82M
2025Q1
1292
127.17M
99.72%
-2.77M
2024Q4
1248
125.34M
101.87%
-989.05K
2024Q3
1210
126.51M
99.20%
+3.13M
2024Q2
1165
122.70M
94.98%
+5.27M
2024Q1
1152
117.38M
97.56%
-6.00M
2023Q4
1149
120.10M
100.10%
-712.55K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Capital World Investors
16.30M
12.29%
-132.48K
-0.81%
Dec 31, 2025
Fidelity Management & Research Company LLC
15.08M
11.37%
-821.92K
-5.17%
Dec 31, 2025
The Vanguard Group, Inc.
13.49M
10.17%
-13.14K
-0.10%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
7.04M
5.31%
+453.92K
+6.89%
Dec 31, 2025
Capital Research Global Investors
6.78M
5.11%
-443.13K
-6.14%
Dec 31, 2025
JP Morgan Asset Management
4.00M
3.01%
+130.78K
+3.38%
Dec 31, 2025
State Street Investment Management (US)
3.23M
2.43%
+147.48K
+4.79%
Dec 31, 2025
Invesco Capital Management (QQQ Trust)
2.81M
2.12%
-68.68K
-2.39%
Feb 28, 2026
Geode Capital Management, L.L.C.
2.65M
2%
+151.48K
+6.06%
Dec 31, 2025
Baillie Gifford & Co.
2.60M
1.96%
-188.38K
-6.75%
Dec 31, 2025
查看更多
持股ETF
更新時間: 12月2日 週二
更新時間: 12月2日 週二
機構名稱
佔比
Global X Genomics & Biotechnology ETF
6.48%
ProShares Ultra Nasdaq Biotechnology
5.81%
Invesco Nasdaq Biotechnology ETF
5.77%
Franklin Genomic Advancements ETF
5.35%
iShares Biotechnology ETF
5.07%
VanEck Biotech ETF
4.56%
American Century Focused Dynamic Growth ETF
3.76%
Goldman Sachs Future Health Care Equity ETF
3.42%
First Trust NYSE Arca Biotechnology Index Fund
3.33%
Invesco NASDAQ Next Gen 100 ETF
3.28%
查看更多
Global X Genomics & Biotechnology ETF
佔比6.48%
ProShares Ultra Nasdaq Biotechnology
佔比5.81%
Invesco Nasdaq Biotechnology ETF
佔比5.77%
Franklin Genomic Advancements ETF
佔比5.35%
iShares Biotechnology ETF
佔比5.07%
VanEck Biotech ETF
佔比4.56%
American Century Focused Dynamic Growth ETF
佔比3.76%
Goldman Sachs Future Health Care Equity ETF
佔比3.42%
First Trust NYSE Arca Biotechnology Index Fund
佔比3.33%
Invesco NASDAQ Next Gen 100 ETF
佔比3.28%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
除權除息日
類型
比率
暫無數據
公告日期
除權除息日
類型
比率
暫無數據
